Cardiovascular risk reduction in hypertension: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers. Where are we up to?
about
Endothelial Dysfunction and Hypertension.Tocotrienol is a cardioprotective agent against ageing-associated cardiovascular disease and its associated morbidities.Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation.Meta-Analysis of the Effects of Foods and Derived Products Containing Ellagitannins and Anthocyanins on Cardiometabolic Biomarkers: Analysis of Factors Influencing Variability of the Individual Responses.
P2860
Cardiovascular risk reduction in hypertension: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers. Where are we up to?
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Cardiovascular risk reduction ...... blockers. Where are we up to?
@en
type
label
Cardiovascular risk reduction ...... blockers. Where are we up to?
@en
prefLabel
Cardiovascular risk reduction ...... blockers. Where are we up to?
@en
P2093
P2860
P356
P1476
Cardiovascular risk reduction ...... blockers. Where are we up to?
@en
P2093
P2860
P304
P356
10.1111/IMJ.12975
P577
2016-03-01T00:00:00Z